Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19
Authors
Keywords
-
Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-12-17
DOI
10.1016/j.cytogfr.2021.12.001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2
- (2021) Romain Lévy et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19)
- (2021) Carolina Scagnolari et al. VIRUS RESEARCH
- Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
- (2021) Megen C. Wittling et al. Frontiers in Immunology
- Trained Immunity: Reprogramming Innate Immunity in Health and Disease
- (2021) Siroon Bekkering et al. Annual Review of Immunology
- Considering personalized Interferon-β therapy for COVID-19
- (2021) Karim Dorgham et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia
- (2021) Nicolas de Prost et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies
- (2021) Ailar Nakhlband et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2
- (2021) Paul Bastard et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics
- (2021) Konstantin Chumakov et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interferon system deficiencies exacerbating severe pandemic virus infections
- (2021) Silke Stertz et al. TRENDS IN MICROBIOLOGY
- Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial
- (2021) Ilad Alavi Darazam et al. Scientific Reports
- How to Train Your Dragon: Harnessing Gamma Delta T Cells Antiviral Functions and Trained Immunity in a Pandemic Era
- (2021) Jonathan Caron et al. Frontiers in Immunology
- Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19
- (2021) Carly G.K. Ziegler et al. CELL
- Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19
- (2021) Benjamin Krämer et al. IMMUNITY
- Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators
- (2021) Daniela Ricci et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
- (2021) Donald C. Vinh et al. JOURNAL OF CLINICAL IMMUNOLOGY
- 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19
- (2021) Niyati Lobo et al. Nature Reviews Urology
- Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study
- (2021) Areej A. Malhani et al. PLoS One
- Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial
- (2021) Eleonora Aricò et al. Trials
- Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
- (2021) Martina Severa et al. PLoS Pathogens
- Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
- (2021) Paul Bastard et al. Science Immunology
- X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19
- (2021) Takaki Asano et al. Science Immunology
- An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial
- (2021) Ilad Alavi Darazam et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection
- (2020) Jean-Laurent Casanova et al. CELL
- Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
- (2020) Zhuo Zhou et al. Cell Host & Microbe
- Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
- (2020) Annsea Park et al. Cell Host & Microbe
- The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic
- (2020) EUROPEAN JOURNAL OF HUMAN GENETICS
- Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung
- (2020) Juho Jalkanen et al. INTENSIVE CARE MEDICINE
- Health inequity during the COVID-19 pandemic: a cry for ethical global leadership
- (2020) David Chiriboga et al. LANCET
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial
- (2020) Effat Davoudi-Monfared et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?
- (2020) Eleonora Aricò et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
- (2020) Farzaneh Dastan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
- (2020) Jérôme Hadjadj et al. SCIENCE
- Activation and evasion of type I interferon responses by SARS-CoV-2
- (2020) Xiaobo Lei et al. Nature Communications
- Could the Induction of Trained Immunity by β-Glucan Serve as a Defense Against COVID-19?
- (2020) Anne Geller et al. Frontiers in Immunology
- BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy
- (2020) Madhuri Koti et al. Journal for ImmunoTherapy of Cancer
- Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly
- (2020) Evangelos J. Giamarellos-Bourboulis et al. CELL
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
- (2020) Qian Zhang et al. SCIENCE
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19
- (2020) Paul Bastard et al. SCIENCE
- SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2
- (2020) Jingfang Mu et al. Cell Discovery
- Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
- (2020) Faryal Khamis et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- NOD2-dependent BCG-induced trained immunity: A way to regulate innate responses to SARS-CoV2?
- (2020) Dhammika Leshan Wannigama et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers
- (2020) Magali Noval Rivas et al. JOURNAL OF CLINICAL INVESTIGATION
- BCG vaccination in health care providers and the protection against COVID-19
- (2020) Mihai G. Netea et al. JOURNAL OF CLINICAL INVESTIGATION
- Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison
- (2020) Ioanna-Evdokia Galani et al. NATURE IMMUNOLOGY
- Combining Antivirals and Immunomodulators to Fight COVID-19
- (2020) Vincent Feuillet et al. TRENDS IN IMMUNOLOGY
- Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients
- (2020) Parvaneh Baghaei et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Type I interferons in tuberculosis: Foe and occasionally friend
- (2018) Lúcia Moreira-Teixeira et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Autocrine Type I IFN Signaling in Dendritic Cells Stimulated with Fungal β-Glucans or Lipopolysaccharide Promotes CD8 T Cell Activation
- (2016) Nargess Hassanzadeh-Kiabi et al. JOURNAL OF IMMUNOLOGY
- Role of type I interferon in inducing a protective immune response: Perspectives for clinical applications
- (2015) Paola Rizza et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use
- (2015) Guido Antonelli et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Interferons: Success in anti-viral immunotherapy
- (2014) Fan-ching Lin et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Type I Interferon Signaling Pathway Is a Target for Glucocorticoid Inhibition
- (2010) J. R. Flammer et al. MOLECULAR AND CELLULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started